Compare Amer Sports Inc (AS) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amer Sports Inc vs Merck & Co., Inc. — how do they compare? Amer Sports Inc trades at $34.44 (market cap $20.25B), while Merck & Co., Inc. trades at $123.66 (market cap $305.12B). The key difference: Merck & Co., Inc. is far larger — about 15.1× Amer Sports Inc's market cap, and Merck & Co., Inc. pays a 2.75% dividend while Amer Sports Inc pays none. Which is the better fit depends on your goals.
| AS | MRK | |
|---|---|---|
Market Cap | $20.25B | $305.12B |
Sector | Technology | Health |
52-Week High | $41.96 | $129.52 |
52-Week Low | $29.54 | $77.60 |
Enterprise Value | $20.56B | $348.54B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amer Sports (AS) trades at $34.80, up 2.75% today, with strong Q1 2026 earnings beating estimates and raised full-year guidance. Technicals show a bearish trend near key support at $33, while fundamentals reflect robust revenue growth of 32% year-over-year and a 58.23% gross margin. Analyst sentiment is overwhelmingly positive with 12 buy ratings and a $56 consensus target, indicating 61% upside potential from current levels.
The outlook remains favorable given earnings momentum and raised guidance, but risks include reliance on Arc'teryx brand sustainability and competitive pressures. Valuation metrics like a P/E of 43.49 suggest premium pricing, requiring continued execution to justify upside. Net positive cash flow and institutional support provide stability amid technical weakness.
Merck (MRK) trades at $123.585, up 0.04% on the day, with a bullish technical signal and strong institutional interest. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a favorable analyst consensus.
The outlook for MRK is positive, supported by earnings beats, a high analyst buy rating (67.57%), and a consensus price target of $135.14. Key risks include rising debt levels and potential regulatory pressures, but the stock's solid fundamentals and acquisition strategy present a compelling opportunity for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amer Sports Inc
Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.
Read more on AS →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
